Your browser doesn't support javascript.
loading
From Mechanism-Based Retaining Glycosidase Inhibitors to Activity-Based Glycosidase Profiling.
Artola, Marta; Aerts, Johannes M F G; van der Marel, Gijsbert A; Rovira, Carme; Codée, Jeroen D C; Davies, Gideon J; Overkleeft, Herman S.
Affiliation
  • Artola M; Leiden Institute of Chemistry, Leiden University, 2300 RA, Leiden, The Netherlands.
  • Aerts JMFG; Leiden Institute of Chemistry, Leiden University, 2300 RA, Leiden, The Netherlands.
  • van der Marel GA; Leiden Institute of Chemistry, Leiden University, 2300 RA, Leiden, The Netherlands.
  • Rovira C; Departament de Química Inorgànica I Orgànica & IQTCUB, Universitat de Barcelona, Barcelona 08028, Spain.
  • Codée JDC; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08020, Spain.
  • Davies GJ; Leiden Institute of Chemistry, Leiden University, 2300 RA, Leiden, The Netherlands.
  • Overkleeft HS; Department of Chemistry, The University York, Heslington, York YO10 5DD, United Kingdom.
J Am Chem Soc ; 146(36): 24729-24741, 2024 Sep 11.
Article in En | MEDLINE | ID: mdl-39213505
ABSTRACT
Activity-based protein profiling (ABPP) is an effective technology for the identification and functional annotation of enzymes in complex biological samples. ABP designs are normally directed to an enzyme active site nucleophile, and within the field of Carbohydrate-Active Enzymes (CAZymes), ABPP has been most successful for those enzymes that feature such a residue retaining glycosidases (GHs). Several mechanism-based covalent and irreversible retaining GH inhibitors have emerged over the past sixty years. ABP designs based on these inhibitor chemistries appeared since the turn of the millennium, and we contributed to the field by designing a suite of retaining GH ABPs modeled on the structure and mode of action of the natural product, cyclophellitol. These ABPs enable the study of both exo- and endo-acting retaining GHs in human health and disease, for instance in genetic metabolic disorders in which retaining GHs are deficient. They are also finding increasing use in the study of GHs in gut microbiota and environmental microorganisms, both in the context of drug (de)toxification in the gut and that of biomass polysaccharide processing for future sustainable energy and chemistries. This account comprises the authors' view on the history of mechanism-based retaining GH inhibitor design and discovery, on how these inhibitors served as blueprints for retaining GH ABP design, and on some current and future developments on how cyclophellitol-based ABPs may drive the discovery of retaining GHs and their inhibitors.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Enzyme Inhibitors / Glycoside Hydrolases Limits: Humans Language: En Journal: J Am Chem Soc Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Enzyme Inhibitors / Glycoside Hydrolases Limits: Humans Language: En Journal: J Am Chem Soc Year: 2024 Document type: Article